A Study of LY3484356 in Women With Breast Cancer Before Having Surgery (EMBER-2)

The purpose for this study is to see if the study drug, LY3484356, is safe and to determine what effects it has on breast cancer in participants with Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) early stage (stage I-III) breast cancer, when given prior to surgery.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Breast Cancer
What the trial is testing?
imlunestrant (LY3484356)
Could I receive a Placebo?
No
Enrollment Goal
86
Trial Dates
Apr 21, 2021 - Nov 11, 2022
How long will I be in the trial?
Participation in this study could last up to 2.5 months.
Trial Phase
I

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer)

  • Participants must be able to swallow capsules)

  • Participants must be willing to be available for the duration of the study and are willing to follow study procedures

Participants Must Not:

  • Participants must not be pregnant or breastfeeding

  • Participants must not plan to receive other treatment for breast cancer during study

  • Participants must not have major surgery within 28 days of starting study treatment

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources